Rituximab and dose dense chemotherapy in primary breast lymphoma

* Oncology Research Unit; ° Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F Correspondence: Agustin Avilés MD, Plaza Luis Cabrera 5-502, Colonia Roma, 06700, México, D.F. Mexico. Phone: international +52.55.56276959. E-mail: agustin.aviles{at}imss.gob.mx Treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2007-08, Vol.92 (8), p.1147-1148
Hauptverfasser:	Aviles, Agustin, Castaneda, Claudia, Neri, Natividad, Cleto, Sergio, Jesus Nambo, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - radiotherapy Breast Neoplasms - therapy Combined Modality Therapy Disease-Free Survival Epirubicin - administration & dosage Female Granulocyte Colony-Stimulating Factor - administration & dosage Hematologic Diseases - chemically induced Humans Immunotherapy Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - radiotherapy Lymphoma, Non-Hodgkin - therapy Middle Aged Nervous System Diseases - chemically induced Prednisone - administration & dosage Rituximab Survival Analysis Treatment Outcome Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	* Oncology Research Unit; ° Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F Correspondence: Agustin Avilés MD, Plaza Luis Cabrera 5-502, Colonia Roma, 06700, México, D.F. Mexico. Phone: international +52.55.56276959. E-mail: agustin.aviles{at}imss.gob.mx Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87%), event free-survival (75%) and overall survival (63%) compared with historical patients. Key words: rituximab, chemotherapy, primary breast lymphoma.
ISSN:	0390-6078 1592-8721
DOI:	10.3324/haematol.10892